American Peptide Company appoints two

Reflects ongoing commitment to provide better customer support

American Peptide Company, a US manufacturer of peptides and peptide-based services to the pharmaceutical and life science industries, has promoted Stewart Hamilton, who has its European sales representative since 2005, to sales and marketing director for the region.

In addition, Stuart White has joined the company as its US East Coast sales executive. White was most recently principal at Actif Bioresources, where he created supply networks dealing in products for therapeutic, mechanistic and academic studies.

‘The new appointments reflect the American Peptide Company’s ongoing commitment to providing better customer support and technical expertise to customers globally, helping them bring new drugs to market faster,’ said Takahiro Ogata, president and coo of American Peptide Company.

In December 2009, the company took on five new members of staff to enhance its technical capabilities.

You may also like

Ingredients

Bachem acquires American Peptide Company

No financial details have been disclosed
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients
CPPs: beating drug delivery barriers

CPPs: beating drug delivery barriers

Cell-penetrating peptides are a promising tool for cellular import of drug cargos and have been applied in the delivery of a variety of therapeutic molecules. Jyothi Thundimadathil and Archana Gangakhedkar, American Peptide Co, highlight recent application studies
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients
Bicyclic peptides for a new class of targeted drugs

Bicyclic peptides for a new class of targeted drugs

Bicyclic peptides are an emerging class of molecules used to explore new cellular sites not treatable using small molecules or large antibodies. Archana Gangakhedkar, American Peptide Company, reveals some of the properties that offer a new route to targeting diseases
Manufacturing
American Peptide to expand manufacturing capacity at Vista

American Peptide to expand manufacturing capacity at Vista

Move will enable APC to process large-scale peptide production and meet cGMP standards
Ingredients
C2 Pharma launches brinzolamide ophthalmic API

C2 Pharma launches brinzolamide ophthalmic API

C2 Pharma has added brinzolamide to its ophthalmic API portfolio following completion of process validation and submission of a US Drug Master File
Ingredients
dsm-firmenich launches Biond pharmaceutical-grade vitamin portfolio for cell culture and biologics manufacturing

dsm-firmenich launches Biond pharmaceutical-grade vitamin portfolio for cell culture and biologics manufacturing

The range targets critical metabolic pathways supporting cell growth, viability and protein expression — available globally through Brenntag's BYPHAR distribution network ahead of its CPHI Milan debut
Manufacturing
CARBOGEN AMCIS announces successful first FDA pre-approval inspection at its Vionnaz site

CARBOGEN AMCIS announces successful first FDA pre-approval inspection at its Vionnaz site

CARBOGEN AMCIS part of the Dishman Carbogen Amcis Group, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, is pleased to announce the successful completion of the first U.S. Food and Drug Administration (FDA) Pre-Approval Inspection (PAI) at its Vionnaz facility in Switzerland. The inspection concluded without the issuance of a Form 483
Subscribe now